AstraZeneca to Invest $2 Billion in Maryland Manufacturing Hub
Article Date: 25 November 2025
Source URL: https://www.supplychain247.com/article/astrazeneca-maryland-manufacturing-expansion
Summary
AstraZeneca will invest $2 billion to expand manufacturing in Maryland, increasing capacity at its Frederick biologics facility and building a new clinical manufacturing site in Gaithersburg. The programme is expected to support 2,600 jobs across hiring, construction and retained roles, and aims to bring production of the company’s rare-disease medicines to the U.S. for the first time. Both sites target completion in 2029 and will incorporate AI, automation, data analytics and high environmental standards.
Key Points
- $2 billion investment to expand manufacturing in Maryland (Frederick and Gaithersburg).
- Creates or supports about 2,600 jobs — including 200 skilled roles and 900 construction jobs in Frederick; 100 new jobs, retention of 400 roles and ~1,000 construction jobs in Gaithersburg.
- Frederick site will nearly double biologics commercial capacity and enable onshore production of rare-disease drugs in the U.S. for the first time.
- Gaithersburg will be a new clinical manufacturing facility supporting development and trial supply for innovative molecules.
- Both facilities planned to open in 2029 and will use AI, automation and data analytics and be built to high environmental standards.
- This is AstraZeneca’s fourth U.S. manufacturing expansion in 2025; the company has pledged $50 billion for U.S. medicines manufacturing and R&D and runs 19 U.S. sites.
Content Summary
The article reports AstraZeneca’s announcement to invest $2 billion in Maryland, focusing on two projects: upgrades at an existing biologics plant in Frederick to increase commercial capacity and enable U.S. production of rare-disease medicines, and construction of a new clinical manufacturing facility in Gaithersburg to supply clinical trials. The combined projects are expected to create thousands of construction roles and several hundred permanent skilled and manufacturing jobs, with both sites due by 2029. Officials emphasised the move as bolstering the U.S. medicine supply chain and strengthening Maryland’s biotech ecosystem.
Context and Relevance
For supply-chain, manufacturing and life-science audiences this signals continued onshoring of pharmaceutical manufacturing, investment in advanced manufacturing technologies (AI, automation, analytics) and strengthening of domestic clinical supply capabilities. The expansion supports workforce growth in a biotech cluster (Maryland) and aligns with wider industry trends: resilience-building, localisation of critical drug supply and large-scale capital commitments by major pharma firms.
Author style
Punchy: Big-ticket investment, lots of jobs, and a clear push to keep critical drug production onshore. If you follow pharma manufacturing or regional economic development, this is one to note — it moves the needle.
Why should I read this?
Because it’s a proper indicator that pharma firms are spending serious money to bring critical manufacturing home. Quick read: jobs, timelines, and what this means for supply-chain resilience — all the bits that matter if you work in manufacturing, procurement or regional planning.
Source
Source: https://www.supplychain247.com/article/astrazeneca-maryland-manufacturing-expansion
